Your browser doesn't support javascript.
loading
Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Miles, Linde A; Bowman, Robert L; Merlinsky, Tiffany R; Csete, Isabelle S; Ooi, Aik T; Durruthy-Durruthy, Robert; Bowman, Michael; Famulare, Christopher; Patel, Minal A; Mendez, Pedro; Ainali, Chrysanthi; Demaree, Benjamin; Delley, Cyrille L; Abate, Adam R; Manivannan, Manimozhi; Sahu, Sombeet; Goldberg, Aaron D; Bolton, Kelly L; Zehir, Ahmet; Rampal, Raajit; Carroll, Martin P; Meyer, Sara E; Viny, Aaron D; Levine, Ross L.
Afiliação
  • Miles LA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bowman RL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Merlinsky TR; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Csete IS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ooi AT; Mission Bio, San Francisco, CA, USA.
  • Durruthy-Durruthy R; Mission Bio, San Francisco, CA, USA.
  • Bowman M; Department of Mechanical Engineering, Colorado School of Mines, Golden, CO, USA.
  • Famulare C; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Patel MA; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mendez P; Mission Bio, San Francisco, CA, USA.
  • Ainali C; Mission Bio, San Francisco, CA, USA.
  • Demaree B; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
  • Delley CL; UC-Berkeley-UCSF Graduate Program in Bioengineering, University of California, San Francisco, CA, USA.
  • Abate AR; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
  • Manivannan M; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
  • Sahu S; UC-Berkeley-UCSF Graduate Program in Bioengineering, University of California, San Francisco, CA, USA.
  • Goldberg AD; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Bolton KL; Mission Bio, San Francisco, CA, USA.
  • Zehir A; Mission Bio, San Francisco, CA, USA.
  • Rampal R; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carroll MP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Meyer SE; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Viny AD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Levine RL; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature ; 587(7834): 477-482, 2020 11.
Article em En | MEDLINE | ID: mdl-33116311
ABSTRACT
Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion mutant genes with high variant allele frequencies appear early in leukaemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later1-3. Although bulk sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations. To delineate the clonal framework of myeloid malignancies, we performed single-cell mutational profiling on 146 samples from 123 patients. Here we show that AML is dominated by a small number of clones, which frequently harbour co-occurring mutations in epigenetic regulators. Conversely, mutations in signalling genes often occur more than once in distinct subclones, consistent with increasing clonal diversity. We mapped clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Our findings provide insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Análise Mutacional de DNA / Células Clonais / Análise de Célula Única / Mutação / Transtornos Mieloproliferativos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Análise Mutacional de DNA / Células Clonais / Análise de Célula Única / Mutação / Transtornos Mieloproliferativos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article